Gynecological cancers represent a major health challenge affecting women globally and across Nigeria. Uterine cancer, primarily arising from the endometrium, is the most common pelvic malignancy, frequently linked to prolonged estrogen exposure without progesterone opposition. Risk factors include obesity, nulliparity, late menopause, and tamoxifen use. In contrast, ovarian cancer is notoriously difficult to detect early, often earning the label 'the silent killer' because symptoms mimic routine gastrointestinal discomfort. Ovarian malignancies stem from epithelial, germ, or stromal cells, with epithelial carcinomas being the most prevalent. Understanding the anatomical origin helps midwives explain disease progression to frightened patients and their families.
Spotting warning signs early can save a woman's life. Midwives must listen carefully when women report unusual pelvic symptoms during routine consultations.
Confirming a gynecological malignancy requires a structured combination of clinical examination, imaging, and tissue histology. Initial assessment begins with a thorough bimanual pelvic examination to check for uterine enlargement or adnexal masses.
Transvaginal ultrasonography serves as the primary imaging modality to measure endometrial thickness or visualize ovarian cysts. When endometrial cancer is suspected, an endometrial biopsy is performed in the clinic using a pipelle or via hysteroscopy with dilatation and curettage. For suspected ovarian masses, serum tumor markers like CA-125 provide supportive biochemical data, though they are not exclusively diagnostic due to elevation in benign conditions. Definitive diagnosis always relies on histopathological examination of surgically resected tissue or biopsy samples.
Once a malignancy is confirmed, staging determines how far the cancer has spread within the pelvis and beyond, guiding treatment decisions and estimating prognosis. Gynecological cancers use systems established by the International Federation of Gynecology and Obstetrics (FIGO).
Histological grade, cell type, and patient age also heavily influence overall survival outcomes.
Management strategies for uterine and ovarian cancers depend heavily on the tumor type, stage, and the woman's general health status. Surgery remains the cornerstone of treatment, often involving a total hysterectomy and bilateral salpingo-oophorectomy, alongside staging biopsies. Advanced ovarian cancer frequently requires optimal cytoreductive surgery to remove as much visible tumor mass as possible, followed by platinum-based chemotherapy. Radiation therapy is commonly utilized for endometrial cancer when high-risk features are present. Supportive care runs parallel to active treatment, focusing on aggressive pain management, nutritional support, management of chemotherapy-induced nausea, and psychological counseling to help patients navigate their physical and emotional transformation.
Midwives caring for women with reproductive cancers extend their expertise far beyond clinical procedures, serving as compassionate advocates and educators. Many women face severe social stigma, fear, and misconceptions regarding cancer diagnoses in local communities. Midwives provide safe spaces for patients to express their fears regarding body image, fertility loss, and mortality. Advocacy involves ensuring timely referrals between primary clinics and tertiary oncology centers, cutting through administrative delays. Furthermore, midwives coordinate multidisciplinary care teams, bridge communication gaps between doctors and the family, and offer empathetic end-of-life care when curative options are exhausted.